Farmas USA

QURE, BMS

BMS, uniQure Launch Up-to-$1B+ Gene Therapy Collaboration

http://www.genengnews.com/gen-news-highlights/bms-uniqure-launch-up-to-1b-gene-therapy-collaboration/81251115/

QURE: PT raised to $40 at Piper Jaffray

CLDN

H.C. Wainwright Starts Celladon w/a Buy $31 PT

Cuidado con esta, que la aprobación es poco problable (not satisfied that adequate control of type 1 error by the joint frailty model to be used for primary efficacy analysis of CUPID-2) y además presentaron S3 el día 1 y se ve dilución en el horizonte

ARNA

Patente de procedimiento que no parece demasiado útil.

http://www.streetinsider.com/Corporate+News/Arena+Pharma+%28ARNA%29+Receives+Additional+U.S.+Patent+for+BELVIQ/10437251.html

Nuevo índice de inmunoterapia oncológica: LCINDX

http://www.loncarindex.com/#!announcement/cwph

http://www.thestreet.com/story/13102924/1/stock-index-tracking-red-hot-cancer-immunotherapy-field-launched.html

ONVO

Acuerdo de investigación con L'Orèal

http://d1lge852tjjqow.cloudfront.net/CIK-0001497253/09ac06b7-8229-44f4-b930-85179e6a356e.pdf?noexit=true

CYTX

Cytori’s ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma

http://www.streetinsider.com/Corporate+News/Cytori+Therapeutics+%28CYTX%29+ECCS-50+Granted+Orphan+Status+by+European+Medicines+Agency/10437401.html?si_client=intbro

Novavax Inc. (NASDAQ: NVAX) was reiterated Buy with a $12 fair value estimate (versus a $7.81 close) at Janney Capital Markets. The firm believes that a data-heavy 2015 will continue driving the shares higher.

Recordemos que Janney Capital Markets dio PO de 11$ en Septiembre 2014.

Read more: Top Analyst Upgrades and Downgrades: AmEx, BIND, Devon, GM, Novavax, Teck and More - American Express (NYSE:AXP) - 24/7 Wall St. http://247wallst.com/investing/2015/04/07/top-analyst-upgrades-and-downgrades-amex-bind-devon-gm-novavax-teck-and-more/#ixzz3Wd01X7Xs 

NVAX

edito: vaya cagada los de Analyst Ratings, han confundido los datos y le han puesto un PO de 7,81, es decir, downgrade. Pffff :(

http://www.analystratings.net/stocks/NASDAQ/NVAX/?RegistrationCode=SocialMedia-StockTwits

Células

Editorial de Robert Lanza

Hope for regenerative treatments: toward safe transplantation of human pluripotent stem-cell-based therapies

http://www.futuremedicine.com/doi/pdf/10.2217/rme.14.89